BLS Pharmaceuticals (FRA:PR80) OCF Margin %: -4.13% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PR80 BLS Pharmaceuticals Ltd FRA:PR80
37 GF Score
Price €0.58
GF Value €0.41
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is BLS Pharmaceuticals OCF Margin %?

BLS Pharmaceuticals FRA:PR80 +6.68% 37 OCF Margin % is -4.13% as of Dec. 2025. GuruFocus rates FRA:PR80 with a GF Score™ of 37/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 950 Biotechnology companies, BLS Pharmaceuticals ranks better than 71.58% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. BLS Pharmaceuticals's Cash Flow from Operations for the six months ended in Dec. 2025 was €-0.73 Mil. BLS Pharmaceuticals's Revenue for the six months ended in Dec. 2025 was €17.77 Mil. Therefore, BLS Pharmaceuticals's OCF Margin % for the quarter that ended in Dec. 2025 was -4.13%.

As of today, BLS Pharmaceuticals's current OCF Yield % is 0.91%.

The historical rank and industry rank for BLS Pharmaceuticals's OCF Margin % or its related term are showing as below:

FRA:PR80' s OCF Margin % Range Over the Past 10 Years
Min: -93.12   Med: -9.81   Max: 22.08
Current: 4.26

During the past 13 years, the highest OCF Margin % of BLS Pharmaceuticals was 22.08%. The lowest was -93.12%. And the median was -9.81%.

FRA:PR80's OCF Margin % is ranked better than
71.58% of 950 companies
in the Biotechnology industry
Industry Median: -64.565 vs FRA:PR80: 4.26

BLS Pharmaceuticals OCF Margin % Related Terms

BLS Pharmaceuticals OCF Margin % Historical Data

* Premium members only.

The historical data trend for BLS Pharmaceuticals's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BLS Pharmaceuticals OCF Margin % Chart

BLS Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.54 18.00 -21.93 -38.54 22.08

BLS Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.00 -29.92 23.53 20.91 -4.13

FRA:PR80 vs : OCF Margin % Comparison

For the Biotechnology subindustry, BLS Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BLS Pharmaceuticals OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's OCF Margin % distribution charts can be found below:

* The bar in red indicates where BLS Pharmaceuticals's OCF Margin % falls into.


FRA:PR80
37GF Score
BLS Pharmaceuticals Ltd FRA:PR80
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BLS Pharmaceuticals OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

BLS Pharmaceuticals's OCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=3.543/16.047
=22.08 %

BLS Pharmaceuticals's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.734/17.767
=-4.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -4.13% mean?
BLS Pharmaceuticals (FRA:PR80) has a OCF Margin % of -4.13% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BLS Pharmaceuticals and its competitors. According to the industry distribution chart, BLS Pharmaceuticals ranks #270 out of 950 companies in the Biotechnology industry, placing it in the top 28.4%.
Is BLS Pharmaceuticals' OCF Margin % too high?
BLS Pharmaceuticals' current OCF Margin % is -4.13%. Based on the distribution chart, BLS Pharmaceuticals ranks #270 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BLS Pharmaceuticals has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' OCF Margin % compare to ?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #270 out of 950 companies for OCF Margin %. This puts BLS Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BLS Pharmaceuticals and its competitors. BLS Pharmaceuticals's current OCF Margin % is -4.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (FRA:PR80) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €0.58 — trading 41% above its estimated fair value. The current OCF Margin % is -4.13%. BLS Pharmaceuticals' overall GF Score™ is 37/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BLS Pharmaceuticals (FRA:PR80), the current OCF Margin % is -4.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BLS Pharmaceuticals (FRA:PR80) Overvalued in 2026?

Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued. The current stock price of €0.58 is trading 41% above its estimated GF Value™ of €0.41. GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:PR80:

  • OCF Margin %: -4.13%
  • GF Value™: €0.41 vs. price of €0.58 (41% above fair value)
  • GF Score™: 37/100 with 8 warning signs

No single metric tells the full story. See the FRA:PR80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BLS Pharmaceuticals Business Description

Comparable Companies
Other Exchanges BLS:Australia
Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
37GF Score

Get the complete analysis for FRA:PR80

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.58
Price
€0.41
GF Value